Clinical trial
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal…
NCT00100841 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00100841 |
|---|---|
| Title | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer |
| Official title | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Stage IV Colon Cancer, Stage IV Rectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | cetuximab, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil |
| Enrollment | 66 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Jan 7, 2005 |
| Last update posted | Jul 27, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: